Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CT-95
- Development stage
- Phase 1
- Lead developer
- Context Therapeutics
- Modality
- Antibody-Based Therapeutics
01
Overview
CT-95 (Context Therapeutics): sourced facts only. name: "CT-95 is a mesothelin (MSLN) x CD3 bispecific T cell-redirecting antibody that is entering phase 1 clinical development." [DOI:10.1158/1538-7445.am2025-2139]; target: "CT-95 is a mesothelin (MSLN) x CD3 bispecific T cell-redirecting antibody that is entering phase 1 clinical development." [DOI:10.1158/1538-7445.am2025-2139]; developer: "Context Therapeutics, Philadelphia, PA." [DOI:10.1158/1538-7445.am2025-2139]; modality: "CT-95 is a mesothelin (MSLN) x CD3 bispecific T cell-redirecting antibody that is entering phase 1 clinical development." [DOI:10.1158/1538-7445.am2025-2139]
02
Targets
Mesothelin
Beyond the preview
Go deeper on CT-95.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CT-95.